D. E. Shaw & Co. Inc. Cuts Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

D. E. Shaw & Co. Inc. cut its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 15.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 421,594 shares of the biotechnology company's stock after selling 79,778 shares during the quarter. D. E. Shaw & Co. Inc. owned about 1.98% of Enanta Pharmaceuticals worth $2,424,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ENTA. Barclays PLC raised its holdings in shares of Enanta Pharmaceuticals by 294.2% in the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company's stock worth $285,000 after buying an additional 20,478 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Enanta Pharmaceuticals by 53.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company's stock worth $2,524,000 after acquiring an additional 85,082 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Enanta Pharmaceuticals by 34.1% during the 4th quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company's stock worth $1,109,000 after acquiring an additional 49,050 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Enanta Pharmaceuticals during the 4th quarter valued at about $26,000. Finally, AlphaQuest LLC increased its holdings in shares of Enanta Pharmaceuticals by 16.4% in the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company's stock valued at $128,000 after purchasing an additional 3,137 shares during the period. Institutional investors and hedge funds own 94.99% of the company's stock.

Enanta Pharmaceuticals Trading Up 1.0%

ENTA traded up $0.06 on Friday, reaching $5.81. The stock had a trading volume of 67,695 shares, compared to its average volume of 286,008. The business's 50-day moving average price is $5.42 and its two-hundred day moving average price is $6.44. Enanta Pharmaceuticals, Inc. has a 12-month low of $4.09 and a 12-month high of $17.24. The company has a market cap of $124.20 million, a P/E ratio of -1.17 and a beta of 0.81.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($1.04) by ($0.02). The business had revenue of $14.93 million during the quarter, compared to analysts' expectations of $15.96 million. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. As a group, analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, February 19th. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Finally, JMP Securities restated a "market outperform" rating and issued a $21.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $17.25.

Enanta Pharmaceuticals Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.